Metabolomic profiling identifies novel metabolites associated with cardiac dysfunction.
Cardiac structure
Echocardiography
Genetics
Heart failure
Metabolomics
Myo-inositol
Natriuretic peptide
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 Sep 2024
05 Sep 2024
Historique:
received:
21
05
2024
accepted:
27
08
2024
medline:
6
9
2024
pubmed:
6
9
2024
entrez:
5
9
2024
Statut:
epublish
Résumé
Metabolic comorbidities, such as obesity and diabetes, are associated with subclinical alterations in both cardiac structure/function and natriuretic peptides prior to the onset of heart failure (HF). Despite this, the exact metabolic pathways of cardiac dysfunction which precede HF are not well-defined. Among older individuals without HF in the Multi-Ethnic Study of Atherosclerosis (MESA), we evaluated the associations of 47 circulating metabolites measured by
Identifiants
pubmed: 39237673
doi: 10.1038/s41598-024-71329-y
pii: 10.1038/s41598-024-71329-y
doi:
Substances chimiques
Natriuretic Peptide, Brain
114471-18-0
Peptide Fragments
0
pro-brain natriuretic peptide (1-76)
0
Biomarkers
0
Inositol
4L6452S749
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20694Informations de copyright
© 2024. The Author(s).
Références
Dunlay, S. M., Roger, V. L. & Redfield, M. M. Epidemiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. 14(10), 591–602. https://doi.org/10.1038/nrcardio.2017.65 (2017).
doi: 10.1038/nrcardio.2017.65
pubmed: 28492288
Shah, S. J. et al. Research priorities for heart failure with preserved ejection fraction: National Heart, Lung, and Blood Institute Working Group Summary. Circulation. 141(12), 1001–1026. https://doi.org/10.1161/CIRCULATIONAHA.119.041886 (2020).
doi: 10.1161/CIRCULATIONAHA.119.041886
pubmed: 32202936
pmcid: 7101072
Schiattarella, G. G. et al. Immunometabolic mechanisms of heart failure with preserved ejection fraction. Nat. Cardiovasc. Res. 1(3), 211–222. https://doi.org/10.1038/s44161-022-00032-w (2022).
doi: 10.1038/s44161-022-00032-w
pubmed: 35755006
pmcid: 9229992
Schrimpe-Rutledge, A. C., Codreanu, S. G., Sherrod, S. D. & McLean, J. A. Untargeted metabolomics strategies-challenges and emerging directions. J. Am. Soc. Mass Spectrom. 27(12), 1897–1905. https://doi.org/10.1007/s13361-016-1469-y (2016).
doi: 10.1007/s13361-016-1469-y
pubmed: 27624161
pmcid: 5110944
Zheng, Y. et al. Associations between metabolomic compounds and incident heart failure among African Americans: The ARIC Study. Am. J. Epidemiol. 178(4), 534–542. https://doi.org/10.1093/aje/kwt004 (2013).
doi: 10.1093/aje/kwt004
pubmed: 23788672
pmcid: 3736751
Andersson, C. et al. Metabolomic signatures of cardiac remodelling and heart failure risk in the community. ESC Heart Failure. 7(6), 3707–3715. https://doi.org/10.1002/ehf2.12923 (2020).
doi: 10.1002/ehf2.12923
pubmed: 32909388
pmcid: 7754777
Tahir, U. A. et al. Metabolomic profiles and heart failure risk in black adults: Insights from the Jackson Heart Study. Circ. Heart Fail. 14(1), e007275. https://doi.org/10.1161/CIRCHEARTFAILURE.120.007275 (2021).
doi: 10.1161/CIRCHEARTFAILURE.120.007275
pubmed: 33464957
pmcid: 9158510
Hunter, W. G. et al. Metabolomic profiling identifies novel circulating biomarkers of mitochondrial dysfunction differentially elevated in heart failure with preserved versus reduced ejection fraction: Evidence for shared metabolic impairments in clinical heart failure. J. Am. Heart Assoc. https://doi.org/10.1161/JAHA.115.003190 (2016).
doi: 10.1161/JAHA.115.003190
pubmed: 27473038
pmcid: 5015273
Razavi, A. C. et al. Novel findings from a metabolomics study of left ventricular diastolic function: The Bogalusa Heart Study. J. Am. Heart Assoc. 9(3), e015118. https://doi.org/10.1161/JAHA.119.015118 (2020).
doi: 10.1161/JAHA.119.015118
pubmed: 31992159
pmcid: 7033875
Choi, E. Y. et al. N-terminal pro-B-type natriuretic peptide, left ventricular mass, and incident heart failure: Multi-Ethnic Study of Atherosclerosis. Circ. Heart Fail. 5(6), 727–734. https://doi.org/10.1161/circheartfailure.112.968701 (2012).
doi: 10.1161/circheartfailure.112.968701
pubmed: 23032197
pmcid: 4124746
Agarwal, S. K. et al. Prediction of incident heart failure in general practice: The Atherosclerosis Risk in Communities (ARIC) Study. Circ. Heart Fail. 5(4), 422–429. https://doi.org/10.1161/circheartfailure.111.964841 (2012).
doi: 10.1161/circheartfailure.111.964841
pubmed: 22589298
pmcid: 3412686
Reimer Jensen, A. M. et al. Association of left ventricular systolic function with incident heart failure in late life. JAMA Cardiol. 6(5), 509–520. https://doi.org/10.1001/jamacardio.2021.0131 (2021).
doi: 10.1001/jamacardio.2021.0131
pubmed: 33729428
pmcid: 7970394
de Simone, G., Gottdiener, J. S., Chinali, M. & Maurer, M. S. Left ventricular mass predicts heart failure not related to previous myocardial infarction: The Cardiovascular Health Study. Eur. Heart J. 29(6), 741–747. https://doi.org/10.1093/eurheartj/ehm605 (2008).
doi: 10.1093/eurheartj/ehm605
pubmed: 18204091
Bild, D. E. et al. Multi-ethnic study of atherosclerosis: Objectives and design. Am. J. Epidemiol. 156(9), 871–881. https://doi.org/10.1093/aje/kwf113 (2002).
doi: 10.1093/aje/kwf113
pubmed: 12397006
Inker, L. A. et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N. Engl. J. Med. 367(1), 20–29. https://doi.org/10.1056/NEJMoa1114248 (2012).
doi: 10.1056/NEJMoa1114248
pubmed: 22762315
pmcid: 4398023
Dona, A. C. et al. Precision high-throughput proton NMR spectroscopy of human urine, serum, and plasma for large-scale metabolic phenotyping. Anal. Chem. 86(19), 9887–9894. https://doi.org/10.1021/ac5025039 (2014).
doi: 10.1021/ac5025039
pubmed: 25180432
Hunter, W. G. et al. Metabolomic profiling of cholesterol efflux capacity in a multiethnic population: Insights from MESA. Arterioscler. Thromb. Vasc. Biol. 43(10), 2030–2041. https://doi.org/10.1161/atvbaha.122.318222 (2023).
doi: 10.1161/atvbaha.122.318222
pubmed: 37615111
pmcid: 10521786
Neeland, I. J. et al. Metabolomics profiling of visceral adipose tissue: Results from MESA and the NEO study. J. Am. Heart Assoc. 8(9), e010810. https://doi.org/10.1161/jaha.118.010810 (2019).
doi: 10.1161/jaha.118.010810
pubmed: 31017036
pmcid: 6512086
Tzoulaki, I. et al. Serum metabolic signatures of coronary and carotid atherosclerosis and subsequent cardiovascular disease. Eur. Heart J. 40(34), 2883–2896. https://doi.org/10.1093/eurheartj/ehz235 (2019).
doi: 10.1093/eurheartj/ehz235
pubmed: 31102408
pmcid: 7963131
Lang, R. M. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 28(1), 1-39.e14. https://doi.org/10.1016/j.echo.2014.10.003 (2015).
doi: 10.1016/j.echo.2014.10.003
pubmed: 25559473
Sanders-van Wijk, S. et al. Proteomic evaluation of the comorbidity-inflammation paradigm in heart failure with preserved ejection fraction: Results from the PROMIS-HFpEF study. Circulation. 142(21), 2029–2044. https://doi.org/10.1161/circulationaha.120.045810 (2020).
doi: 10.1161/circulationaha.120.045810
pubmed: 33034202
pmcid: 7686082
Purcell, S. et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81(3), 559–575. https://doi.org/10.1086/519795 (2007).
doi: 10.1086/519795
pubmed: 17701901
pmcid: 1950838
Giro, P. et al. Missense genetic variation of ICAM1 and incident heart failure. J. Card. Fail. 29(8), 1163–1172. https://doi.org/10.1016/j.cardfail.2023.02.003 (2023).
doi: 10.1016/j.cardfail.2023.02.003
pubmed: 36882149
pmcid: 10477308
Buniello, A. et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 47(D1), D1005–D1012 (2019).
doi: 10.1093/nar/gky1120
pubmed: 30445434
Wojcik, G. L. et al. Genetic analyses of diverse populations improves discovery for complex traits. Nature. 570(7762), 514–518. https://doi.org/10.1038/s41586-019-1310-4 (2019).
doi: 10.1038/s41586-019-1310-4
pubmed: 31217584
pmcid: 6785182
Andersson, C. et al. Metabolomic signatures of cardiac remodelling and heart failure risk in the community. ESC Heart Fail. 7(6), 3707–3715. https://doi.org/10.1002/ehf2.12923 (2020).
doi: 10.1002/ehf2.12923
pubmed: 32909388
pmcid: 7754777
Lopaschuk, G. D., Karwi, Q. G., Tian, R., Wende, A. R. & Abel, E. D. Cardiac energy metabolism in heart failure. Circ. Res. 128(10), 1487–1513. https://doi.org/10.1161/circresaha.121.318241 (2021).
doi: 10.1161/circresaha.121.318241
pubmed: 33983836
pmcid: 8136750
Kiani, A. K. et al. From Myo-inositol to D-chiro-inositol molecular pathways. Eur. Rev. Med. Pharmacol. Sci. 25(5), 2390–2402. https://doi.org/10.26355/eurrev_202103_25279 (2021).
doi: 10.26355/eurrev_202103_25279
pubmed: 33755975
Croze, M. L. & Soulage, C. O. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 95(10), 1811–1827. https://doi.org/10.1016/j.biochi.2013.05.011 (2013).
doi: 10.1016/j.biochi.2013.05.011
pubmed: 23764390
Thomas, M. P., Mills, S. J. & Potter, B. V. The “other” inositols and their phosphates: Synthesis, biology, and medicine (with recent advances in myo-inositol chemistry). Angew. Chem. Int. Ed. Engl. 55(5), 1614–1650. https://doi.org/10.1002/anie.201502227 (2016).
doi: 10.1002/anie.201502227
pubmed: 26694856
Mueller-Hennessen, M. et al. A novel lipid biomarker panel for the detection of heart failure with reduced ejection fraction. Clin. Chem. 63(1), 267–277. https://doi.org/10.1373/clinchem.2016.257279 (2017).
doi: 10.1373/clinchem.2016.257279
pubmed: 28062623
Deidda, M. et al. Metabolomic approach to profile functional and metabolic changes in heart failure. J. Transl. Med. 13(1), 297. https://doi.org/10.1186/s12967-015-0661-3 (2015).
doi: 10.1186/s12967-015-0661-3
pubmed: 26364058
pmcid: 4567812
Alexander, D., Lombardi, R., Rodriguez, G., Mitchell, M. M. & Marian, A. J. Metabolomic distinction and insights into the pathogenesis of human primary dilated cardiomyopathy. Eur. J. Clin. Investig. 41(5), 527–538. https://doi.org/10.1111/j.1365-2362.2010.02441.x (2011).
doi: 10.1111/j.1365-2362.2010.02441.x
McKirnan, M. D. et al. Metabolomic analysis of serum and myocardium in compensated heart failure after myocardial infarction. Life Sci. 221, 212–223. https://doi.org/10.1016/j.lfs.2019.01.040 (2019).
doi: 10.1016/j.lfs.2019.01.040
pubmed: 30731143
pmcid: 6445392
Dinicola, S. et al. Inositols: From established knowledge to novel approaches. Int. J. Mol. Sci. https://doi.org/10.3390/ijms221910575 (2021).
doi: 10.3390/ijms221910575
pubmed: 34638926
pmcid: 8508595
DiNicolantonio, J. J. & Okeefe, J. H. Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes. Open Heart. https://doi.org/10.1136/openhrt-2022-001989 (2022).
doi: 10.1136/openhrt-2022-001989
pubmed: 36522127
pmcid: 9756291
Al-Khelaifi, F. et al. Metabolic GWAS of elite athletes reveals novel genetically-influenced metabolites associated with athletic performance. Sci. Rep. 9(1), 19889. https://doi.org/10.1038/s41598-019-56496-7 (2019).
doi: 10.1038/s41598-019-56496-7
pubmed: 31882771
pmcid: 6934758
El-Aroussy, W. et al. Plasma carnitine levels as a marker of impaired left ventricular functions. Mol. Cell Biochem. 213(1–2), 37–41. https://doi.org/10.1023/a:1007142919941 (2000).
doi: 10.1023/a:1007142919941
pubmed: 11129956
Zordoky, B. N. et al. Metabolomic fingerprint of heart failure with preserved ejection fraction. PLoS ONE. 10(5), e0124844. https://doi.org/10.1371/journal.pone.0124844 (2015).
doi: 10.1371/journal.pone.0124844
pubmed: 26010610
pmcid: 4444296
Almannai, M., Alfadhel, M. & El-Hattab, A. W. Carnitine inborn errors of metabolism. Molecules. https://doi.org/10.3390/molecules24183251 (2019).
doi: 10.3390/molecules24183251
pubmed: 31500110
pmcid: 6766900
Hahn, V. S. et al. Myocardial metabolomics of human heart failure with preserved ejection fraction. Circulation. 147(15), 1147–1161. https://doi.org/10.1161/circulationaha.122.061846 (2023).
doi: 10.1161/circulationaha.122.061846
pubmed: 36856044
pmcid: 11059242
Marcovina, S. M. et al. Translating the basic knowledge of mitochondrial functions to metabolic therapy: Role of L-carnitine. Transl. Res. 161(2), 73–84. https://doi.org/10.1016/j.trsl.2012.10.006 (2013).
doi: 10.1016/j.trsl.2012.10.006
pubmed: 23138103
Zhang, Z. Y. et al. Diastolic left ventricular function in relation to circulating metabolic biomarkers in a population study. Eur. J. Prev. Cardiol. 26(1), 22–32. https://doi.org/10.1177/2047487318797395 (2019).
doi: 10.1177/2047487318797395
pubmed: 30196724
Brown, D. A. et al. Mitochondrial function as a therapeutic target in heart failure. Nat. Rev. Cardiol. 14(4), 238–250 (2017).
doi: 10.1038/nrcardio.2016.203
pubmed: 28004807
Reitzer, L. J., Wice, B. M. & Kennell, D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J. Biol. Chem. 254(8), 2669–2676 (1979).
doi: 10.1016/S0021-9258(17)30124-2
pubmed: 429309
Kennel, P. J. et al. Impairment of myocardial glutamine homeostasis induced by suppression of the amino acid carrier SLC1A5 in failing myocardium. Circ. Heart Fail. 12(12), e006336. https://doi.org/10.1161/circheartfailure.119.006336 (2019).
doi: 10.1161/circheartfailure.119.006336
pubmed: 31826641
He, X. & Slupsky, C. M. Metabolic fingerprint of dimethyl sulfone (DMSO2) in microbial-mammalian co-metabolism. J. Proteome Res. 13(12), 5281–5292. https://doi.org/10.1021/pr500629t (2014).
doi: 10.1021/pr500629t
pubmed: 25245235
Engelke, U. F. H. et al. Dimethyl sulfone in human cerebrospinal fluid and blood plasma confirmed by one-dimensional 1H and two-dimensional 1H–13C NMR. NMR Biomed. 18(5), 331–336. https://doi.org/10.1002/nbm.966 (2005).
doi: 10.1002/nbm.966
pubmed: 15996001
Marques, F. Z. et al. High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice. Circulation. 135(10), 964–977. https://doi.org/10.1161/circulationaha.116.024545 (2017).
doi: 10.1161/circulationaha.116.024545
pubmed: 27927713